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Encapsulation of cytotoxic or labile drugs enables targeted delivery and sustained release kinetics that are not
available with intravenous injection. A new liquid-liquid diffusion process has been developed for forming unique
microcapsules that contain both aqueous and hydrocarbon soluble drugs. Microgravity experiments, on sounding
rockets (1989-92) and Shuttle missions STS-52 (1992) and STS-56(1993) using an automated Materials Dispersion
Apparatus, produced multi-lameilar microcapsules containing both Cis-platinum (anti-tumor drug) and iodinated
poppy seed oil (a radiocontrast medium), surrounded by a polyglyceride skin. Microcapsules fomled with amoxicillin
(antibiotic) or urokinase (a clot dissolving enzyme), co-encapsulated with IPO, are still intact after two years.
Microcapsules were formed with the drug so concentrated that crystals formed inside. Multi-layered microspheres,
with both hydrophobic and hydrophilic drug compartments, can enable diffusion of complimentary drugs from the
same microcapsule, e.g. antibiotics and immuno-stimulants to treat resistant infections or multiple fibrinolytic drags
to dissolve emboli. Co-encapsulation of enough radio-contrast medium enables oncologists to monitor the delivery
of anti-tumor microcapsules to target tumors using computerized tomography and radiography that would Irack the
dislribution of microcapsulcs after release from the inlra-arterial catheter. These microcapsules could have important
applications in chemotherapy of certain liver, kidney, brain and other tumors.
BACKGROUND
Many cytotoxic or bioactive drugs and enzymes cannot he injected intravenously. Others can be injected, but
are rapidly degraded before they reach the target tissue or they are cleared from the blood so quickly that their useful
biological half-life is too short for good therapeutic value. Many drugs are insoluble in aqueous solutions and
intravenous injection in hydrocarbon solvents is not well tolerated by patients. Encapsulation of drugs or biological
therapeutics into liposomes or liquid microcapsules can enable delivery to target organs where the bioactive drug can he
releaseddirectly to the target area by diffusion. Properly designed microcapsules can provide unique methods of direct
delivery by parenteral injection, nasal inhalation and dermal administration for sustained release of important bioactive
drugs [1]. The size and shape of the microcapsules is critical for the distribution and drug delivery in the tissues.
Typically, microcapsules of 1-5 micron diameter are optimum for intravenous administration, whereas, 200-300
micron diameter microcapsules are used for intra-arterial delivery. Perfect microspheres are needed for maximum
packing densities and maximum drug payload delivery to target organs or tumors. Anti-tumor liposomes containing
doxorubicin [2] or muramyltripeptide [3] have already been studied extensively in clinical trials. The disadvantages of
using conventional liposomes or microcapsules include manufacturing methods that require many batch process steps
to: 1) form the liposomes, 2) remove unwanted organic solvents, detergents, and 3) to harvest the proper size micro-
particles for optimum pharmacologic efficiacy [4]. Also conventional liposomes often use natural lipids and lectins
(from eggs, soybeans and other inexpensive sources) which attract certain phagocytic immune cells that rapidly remove
the liposomes from the circulatory system before they arrive at the target tissue. This creates variable dose-responses
which greatly complicates the pharmacokinetics and makes calculations of therapeutic doses very difficult [5]. New
formulations of "stealth" liposomes have been made with lipids that are less detectable by immune cells in an attempt
to avoid phagocytosis [6], however, new types of liposomes and microcapsules are needed to exploit the various unique
applications of this type of drug delivery.




Current methods of forming liposomes are based on mechanisms that certain phospholipids exhibit by
arranging themselves into bilayers when they are dispersed in an excess of water. Above the main transition temp-
erature, which can vary from -20 to +90 °C (depending on the nature of the pbospholipid), these bilayers spontane-
ously form microspheres that entrap an aqueous core. Drugs that are soluble in organic solvents arc usually limited
to those that bind inside the hydrophobic region of the liposome bilayer. However, most drugs are dissolved in the
aqueous phase which is entrapped when the liposome forms and the drug is either incorporated into the aqueous core
or electrstatically binds to the polar regions of the bilayer. Some drugs are insoluble and are not associated with the
bilayer therefore these have very low encapsulation efficiencies. Table 1 summarizes the major classes of drugs that
are used in liposome formulations. Major difficulties with commercial preparation of microcapsules often involves
density-driven phase separation of the immiscible carder fluids, esp. when forming water/oil emulsions or trying to
encapsulate multiple drugs. This limits the yield and often results in microparticles that are not spherical nor
uniform in size, thereby limiting the packing density (and drug payload delivered) when the microcapsules arrive at
the target tissues.




Bi-layer associated - electrostatic interaction
Neither water-soluble, nor bi-layer associated
LOCATION IN LIPOSOME
Aqueous phase, usually inner core
Bound inside hydrophobic region of bi-layer
Outer or inner polar regions of bi-layer






Microcapsule formation by liquid-liquid dispersion of aqueous drugs and organic solvents typically produces
water-in-oil (W/O) type liposomes, which then require the organic solvent to be removed (evaporated) to form
reverse-phase evaporation vesicles (rev) or stable pluri-lamellar vesicles (splv). Multi-lamellar vesicles (mlv) are
rarely formed by these methods, but usually require film casting with organic solvents, hydration and sizing using
f'dtration through inert membrane filters [4]. Methods of forming multi-layered microencapsules often require
emulsification of the aqueous phase into organic carrier solutions by shear, bubbling or sonication. Sophisticated,
multi-step emulsion technology is required and yields of uniform type and size are often very low.
Liquid microemulsions also are being developed as drug delivery systems, especially for drugs that are
poorly soluble in aqueous carriers. A microemulsion typically contains droplets in the range of 0.1 - 1 _t in diameter
and is characterized by very fluid and dynamic micelles which are formed by sequential mixing one immiscible phase
with another using surfactants and co-surfactants [7]. Typically, surfactants that produce water-in-oil (W/O) have a
hydrophilic-lipophilic balance (HLB) rating of 3 to 6, while those that produce oil-in-water (O/W) microemulsions
have an HLB of 8 to 18. The surfactants can be non-ionic, ionic, or amphoteric and often medium chain alcohols
are added as the co-surfactant in the last step in achieving the final microemulsion.
NEW METHODS FOR MICROENCAPSULATION OF DRUGS
In the past few years, new methods have been developed for preparing microspheres specifically designed
for intravascular delivery. The objective is to make the appropriate size microspheres and co-encapsulate both
immiscible phases into microspheres that can withstand the shear forces of intravascular injection and flow through
the blood vessels until they are entrapped at the target site. The outer lipid bilayer or microsphere matrix must also
be designed for drug diffusion, at appropriate release rates, once the microcapsule has reached the target tissue. One
of the authors (Mosier) had invented a new method of preparing microspheres by liquid encapsulation and solid-phase
entrapment wherein the water-soluble drug is dispersed in a solid matrix material [8]. This method involves dissolv-
ing the aqueous drug and the matrix material in a organic solvent, in which they are mutually soluble, then dispers-
ing this mixture in a second organic solven_ to form an emulsion that is stable enough for intravascular injection.
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Dispersion of finely divided solids in liquids or formation of microemulsions including dense materials can be
achieved with similar techniques, however, successful formulations depend upon the interparticle behavior in the
suspensions. For example, when finely divided Cis-platinum (anti-tumor drug), in saline solution, is dispersed in
alcohol solution containing a lipid and surfaclant, dense microspheres will form when the mixture is shaken in a
reciprocating motion. These experiments illustrate a well known phenomenum wherein a second liquid phase (such
as water) causes the solid to be preferentially wet therein causing sticky collisions of tile solid owning to the inter-
facial tension between the two liquid phases, thereby causing dense microspheres to be readily formed. The sediment-
ation rate of the microspheres was found to be quite high compared with the original suspension. This phenomenom
does not occur when Cis-platinum is dispersed in alcohol alone, which suggests that the hydrophilic nature of the
diamino,dichloro, Cis-platinum complex in the hydrophobic polyglyceride solution causes spontaneous emulsifica-
tion. These experiments are unique and offer interesting technical possibilities for separation of suspended solids,
such as Cis-platinum from liquid carriers that have appropriate hydrophilic or hydrophobic characleristics.
Production of multi-layered microspheres with alternate hydrophobic and hydmphilic drug compatUnents
opens up the possibility of developing multiple-therapy microcapsules which can allow sequential diffusion of two
or more drugs out of the same microcapsules once they arrive at the target tissues. In some applications, the organic
phase can include a tracer compound or radiocomrast medium to provide the additional advantage of real-time imaging
of the microcapsules with computerized tomography (CT) scanning as they are released from the catheter and travel
to the target tissue. Practical applications of immiscible, liquid-liquid microcapsule formation are limited, however,
because of denstiy-driven phase separation and stratification into horizonital layers resulting in the necx._sity to use
multi-step batch processing with solvent evaporation phases and mechanical mixing, which often is not practical.
Gravity-dependent restrictions in our two step liquid-liquid spontaneous microencapsulation process led to
the design of several microgravity experiments to explore the utility of this process when density-driven phenomena
were eliminated. The microgravity flight experiments have led to the development of a new liquid-liquid microencap-
sulation process that involves use of surfactants and co-surfactants in the aqueous phase and co-surfactant alcohols in
the organic phase, which also contains high molecular weight lipids that can form a tough outer "skin" on the final
microcapsules. In microgravity a single step dispersion produced unique multi-lamellar microcapsules containing
various aqueous drugs co-encapsulated with iodinated poppy seed oil (a radioconlrast medium with asp. gravity
=1.35). Subsequent ground control experiments also produced some of these unique microcapsules and illustrated
that the 1-g process could be improved to yield useable microcapsules by using different formulations or electrostatic
deposition to add the polymeric, outer coating.
MICROGRAVITY EXPERIMENTS
A collaborative research project was developed by the Institute for Research, Inc. and the Johnson Space
Center starting in July 1987. The basic formulations and simplified liquid-liquid dispersion methods were developed in
1988 and 1989. Microencapsulation related experiments were attempted on eight space missions beginning in April
1989 with the Consort-1 sounding rocket using the Materials Dispersion Apparatus (MDA) mini-lab developed by
Instrumentation Technology Associates, Inc. The sounding rocket flights produced only 6.5 minutes of microgravity
conditions, but this was adequate to form the unique microcapsules in a single step. Experiments on the Space Shuttle
permitted 10 minute dispersion times followed by curing of the outer polyglyceride skin for eight days under miocro-
gravity conditions. A summary of these experiments is shown in Table 2. New formulations were tested on Shuttle
STS-52, using only aqueous-soluble drugs, polymers and surfactants, and on STS-56 using alcohols as co-surfactants.
Sounding rocket ex_oerimeot_
Initial experiments on Consort-1 and -3 were used to determine the effective mixing and diffusion kinetics in
the MDAs. The f'wst drug encapsulation experiments were attempted on the Joust-1 rocket, but the rocket was destroyed
shortly after launch. The next attempt was on the Shuttle STS-43 mission, however, the experiment fluids were
removed after a launch delay and concern about possible internal leakage of the alcohol solutions resulted in a decision
to not reload the MDAs with the microencapsulation fluids. The first successful microencapsulation of drugs in
microgravity was conducted on the Consort-4 mission in November 1991. The unique microcapsules were recovered
and analysed by microscopic image analysis. Mono-dispersed fluorescent beads were included as internal size standards
and fluorescent labels were used to determine the distribution of drug in the various fluid compartments. Additional
experiments, conducted on Consort-5 in September 1992, conf'u'med the capabilities of the new method for forming
multi-lamellar microcapsules with alternating layers of hydrophilic and hydrophobic drugs.
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Table 2. IVIED Flight Experiments Summary:
DATE
Consort 1 AI_I 1989








JOUST -1, June 1991 Lipid Emulsions a Urokinase & antibodies None - Launch aborted
STS-43 July 1991 Lipid Emulsions a Strept-avadin, Urokinase
& Cis-Platinum
Expt. removed after 1st
launch scrub














STS-52 Oct. 1992 Microencapsulation Cis-Platinum, Amoxicillin
of Drugs a b & Urokinase
(aqueous polymers only)
STS-56 April 1993 Microencapsulation Cis-Platinum, Amoxicillin






a Fluorescent labels included "b-Fluorescent beads included
Microcapsules formed in 36 microgravity mini-experiments on sounding rockets used liquid-liquid dispersion
of aqueous drug solutions, surfactant, and polyethylene glycol dispersed in alcoholic co-surfactant solutions containing
soluble polyglycerides. Microcapsules of both oil/water and polymer/water/oil were recovered from the Consort flights.
These experiments produced multi-lamellar liquid microspheres (concentric spheres within spheres) comprised of three
or more, alternating immiscible layers. Image analysis of the microcapsules was made possible by co-encapsulation of
standard size fluorescent beads. Microcapsules were formed in the ranges of 1-15 Ix, 40-50 Ix, 110-130 Ix and 160-230 Ix
diameters. Digital analysis of phase contrast and fluorescent images taken with a fluorescent microscope also confirmed
that the aqueous-souble drugs were often encapsulated within the inner aqueous core and the outermost aqueous shell of
the mierocapsules. This typical distribution is illustrated in Figure 1, which is a composite of a transmitted light
photomicrograph and a fluorescent photomicrograph (lower righ0 of the same multi-lamellar microcapsule. The
polyglyceride skin is clearly shown in the normal-light photomicrograph (upper left).
Muitilamellar microspheres were also formed which contained relatively large amounts of IPO in discrete
lameUa or vesicles. Figure 2 (left side) shows a microcapsule heavily loaded with IPO, which often comprised up to
38% of the total volume. Often small hemispheres of IPO were also found clinging to the outer surface of the large
inner (aqueous) sphere or adhered to the outer polymer skin of the microeapsule as also shown in Figure 2 (upper
center). Mierocapsules formed by almost all of the formulations survived 15+g accelerations, severe vibrations and
turbulent mixing, during the reentry of the experiment capsule, and have remained intact for two years after recovery
from space. These multi-layered mierocapsuies are similar to liquid-filled, thin-skinned, micro-balloons which are
flexible enough to be manipulated on a microscope slide without collapse. The microcapsules formed in just 6.5
minutes of micro-g retain their spherical shape and appear tough enough to survive the extensive physical
manipulations required for sizing, final preparation and storage of patenteral suspensions, and the fluid shear
encountered after intravascular injection. Augmented mixing, under microgravity condition, using finely dispersed
iron particles drawn through the immiscible interface by a small magnetic field was also used to form microcapsules
containing hydmphilic drugs, microbeads, and hydrophobic componets.
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Also we have formed very unusual structures (multiple small spheres of aqueous-soluble drug) distributed
within multi-lamellar o/w/o microspheres, wherein the aqueous spheriods are arranged in an annular ring that
appears f'Lxed in a plane within the innermost sphere ( not shown). These ring structures remain intact when the
microcapsules are "roiled around" on the microscope slide.
Space Shuttle Ex_veriment._
Microencapsulation experiments on Consort 4 and Consort 5 used mixtures of aqueous-soluble drugs, IPO,
C3-C8 alcohols and polyglycerides that are insoluble in aqueous solutions. Experiments on STS-52 co-encapsulated
Cis-Platinum with IPO by forming liposomes from water-soluble polymers using special formulations of aqueous,
non-alcoholic solvents. Polyvinyl pyrolidone (PVP) and a commercial lethicin (Centrolex-F TM)I were used to
form the liposome-type multi-lameilar microcapsules at 20 °C. Fluorescent beads and fluorescent labeled were co-
encapsulated with the drugs to permit drug-distribution measurements, within the various vesicles and lamellae,
using fluorescence microscopy and digital image analysis at the Johnson Space Center. The final microcapsules
were suspended and recovered in either aqueous solutions, IPO or mineral oil. The microcapsules formed by these
formulations were similar to those made using alcohol-soluble polyglycerides, however, without the hydrocarbon-
soluble polyglyceride skin these microcapsules were more fragile.
Another unique type of microcapsule was formed during these experiments that was characterized by drug
crystals formed within the inner aqueous core of the multi-lamellar microspheres. Figure 3 shows an example of a
microcapsule which is packed (approximately) 65% of the aqueous compartmen0 with crystals of Cis-platinum,
anti-tumor drug. Figure 4 shows two microcapsules containing crystals of amoxicillin that were formed in the STS-
52 experiments. These illustrate that aqueous-soluble drugs can be encapsulated at very high concentrations near the
solubility limit of the drug. After the microcapsules are formed the drug can become further concentrated to form
large crystals which can be more stable than the dissolved drug during prolonged storage.
In 1993 modifications to the MDA flight hardware enabled drug encapsulation experiments to be conducted
on STS-56 at 20 °C. using alcohol solvents for the polyglycerides. Cis-platinum, amoxicillin and urokinase were
each co-encapsulated with IPO, radio-contrast medium, using mixtures of aqueous-soluble polymers, dextran, C3-C6
alcohols (co-surfactants), and polyglycerides that are insoluble in aqueous solutions. These microcapsules were
tougher than those formed on STS-52 using only water soluble polymers. The STS-56 experiments again produced
multi-lamellar liquid microspheres (multiple concentric spheres within spheres) comprised of alternating immiscible
layers. Using fluorescent 6.4 micron beads and image analysis, it was found that the most interesting microcapsules
were formed in the range of 10-15 It, 40-50 It, 50-100 Ix and 160-230 It diameters. More microcapsules were formed
containing crystals of cis-platinum or amoxicillin which were formed after encapsulation. Several microcapsules
were formed that contained a single large cubic crystal of Cis-platinum which so completely filled the inner sphere
that only about 15% of the inner volume remained as a liquid. One encapsulated, cubic Cis-platinum crystal was
measured at 48 It across within a 57 tt diameter microcapsule. (data not shown). After formation, some of the
microspheres were dispersed in an external oil phase (either IPO or mineral oil) and allowed to cure for eight days
before return to Earth.
Our space experiments have shown that formation of multilamellar, alternating-phase microspheres can be
controlled by proper timed-sequence exposures of the immiscible phases using special solvent formulations and
surfactants. Once formed these microcapsules remain spherical due to the predominant surface tension of the internal
phases. High molecular weight polymers and polyglycerides can be included to form flexible, permeable "skins"
around the liquid microcapsules as they are created by phase partitioning mechanisms. These experiments clearly
demonstrated the capability to use liquid-liquid diffusion mixing to form unique microcapsules containing hy-
drophilic and hydrophobic drugs under microgravity conditions. The flexible microcapsules, formed under micro-
gravity conditions, have more uniform size distributions than those formed in I-g, largely due to the absence of
thermal convection and instabilities that occur at the immiscible interfaces. The microgravity experiments illustrate
the feasibility of co-encapsulating aqueous-soluble drugs, hydrocarbon- soluble drugs and oil-based contrast media
within a lipid-soluble, polyglyceride, outer film which cures rapidly enough to be impervious to oil or hydrocarbon
resolubilization. These methods allow the formation and harvesting of unique microcapsules which are durable
enough to be removed from the external solvent without disruption or destruction of the internal phases. These new
mcrocapsules have several advantages over conventional liposomes that are designed for intravascular injection.
1 Centrolex-F TM is a lecithin produced by U.S. Soya, Inc.
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Other Microe_Ans, dn,lon Flight l=xneriments
Previously, aerosol dispersion of agarose-type gels, dissolved in aqueous vehicles, were used to encapsulate
pancreatic cells during short periods of weighdessness (25 seconds) during parabolic flights of the NASA KC-135,
Zexo-g aircraft. These were commercial pilot studiesconducted by file Canadian Aerospace Ltd. and NASA [9]. A
joint microencapsulation program was planned to expand these experiments to use electrophorctic separations to
harvest only those microcapsules containing the pancreatic cells so that animal trials could be conducted to treat
diabetes by Iransplantation of the encapsulated cells that produce insulin.
Microencapsulation in Space (MIS) experiments were also conducted on Shuttle mission STS-53 in
December 1993 under a joint program between the Department of the Anny's Space Technology and Research Off'ce
and Dr. T. Tice, Southern Research Institute, Birmingham, AL., using a traditional approach to aerosol dispe_ion of
ampicillin. The main objectives of the experiments were to compare formation and curing of the liposomes in an
elecuostatic field vs. no electrostatic field, without having the liposomes sediment to the floor of the test chamber.
The results presented in testimony to the U.S. Congress in April 1993 indicate that more uniform liposomes wee
formed in microgravity as compared to the same process on Earth [10].
Flight Hardware Description
The microencapsulation experiments described in this paper were conducted using ITA's automated labora-
tory, the Materials Dispersion Apparatus (MDA). The MDA is a compact device capable of bringing into contact and
mixing up to 100 separate samples of multiple fluids and/or solids at precisely timed intervals.The samples mix
either by simple liquid-liquid diffusion or magnetic mixing techniques. The device also can be used to grow protein
crystals by three different methods and to cast polymer membranes in the absence of thermal convection.
Experiments were conducted on the sounding rocket flights during approximately 6.5 minutes of micr-
gravity and two Space Shuttle missions which lasted 8 days. The fluid volumes were 500 microliters per sample.
Approximately 8-10 microencapsulation experiments were conducted on each flight. The MDA's consist of an upper
and a lower block that contain chambers for each sample fluid. The blocks are misaligned at launch so that the
chambers are not in contact with each other. Upon activation in microgravity, the blocks are moved to align the
chambers so that the fluids can mix by liquid to liquid diffusion. For some experiments, a single-step, magnetic-
mixing technique was utilized to accelerate the process. Some of the experiments were conducted with a single-step
fluid mixing, and some were done with a two-step fluid mixing technique which allows diffusion of a third fluid or
sample into the mixture of the first two fluids while still in the microgravity environment. Figure 5 shows four
MDA Minilabs ready for experiments to be conducted on the Consort sounding rocket flights. Two of these MDA
units were used in each sounding rocket and four of the MDA units were utilized in the space shuttle missions.
Figure 6 shows the integrated package ready for a Shuttle flight. The MDAs are completely automated system with
commands being given by an onboard process controller when used on the sounding rockets. When the MDA units
are flown in the Space Shuttle, a controller activated by the crew provides commands to process the samples. In
addition, the MDA minilabs contain a manual back-up mechanism for aswonaut intervention if the controller fails.
As a result of the space experiments conducted in the MDAs a new microencapsulation apparatus is now being
developed by NASA-JSC, IRI and ITA to exploit this technology on Earth and for conducting new flight
experiments dedicated to microencapsulation of drugs under microgravity conditions.
DISCUSSION
Commercially oriented space experiments have shown that microgravity can permit the encapsulation of
drugs into unique microcapsules by liquid-liquid dispersion and spontaneous emulsification using alcohol/water/oil
mixtures, appropriate surfactants, and co-surfaclants [11-14]. Spontaneous formation of multi-lamellar, microcap-
sules containing alternating layers of aqueous and hydrophobic solvent compartments is strongly dependent on the
interfacial tension and the amount of mixing between immiscible liquid phases. On Earth this process is limited by
gravity-dependent, density-driven separation of the immiscible liquids into stratified horizontal layers. In micrograv-
ity, this process is largely dependent on the surface-free energies of the different liquids, but independent of density-
driven convection or bouyant phase separation. Hydrocarbon soluble, high molecular weight polymers have been
included in the formulations to form flexible, permeable "skins" around the liquid microcapsules as they are created
by phase partitioning mechanisms. The microcapsules can be formed and cured without deformation by contact with
container walls. This offers new possibilities for using electric fields to form the microspheres or deposit coatings.
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Co-encapsulation of an aqueous-soluble, anti-tumor drug (Cis-platinum) and a radio-contrast medium (IPO),
in microgravity, has produced a unique drug delivery system that can be visualized by radiologic or computerized
tomography scanning to insure that the cytotoxic drug is delivered directly to the target tumor. Multi-layered
microcapsules have been developed which can provide a new inwavascular delivery system for targeted tissues and
sequential, sustained release of multiple anti-tumor drugs. This method has formed perfect microspheres and more
uniform sizes, which can provide maximum packing densities and maximum drug delivery to target organs or tumors.
The capability to obtain larger, more uniform size microcapsules opens up more possibilities to treat highly
vascular tmnors (liver and kidney) with chemoembolization. Therein, the microcapsules (100-200 it) are injected via
an arterial catheter to form artificial emboli which block the blood supply to the tumor. The reduced blood volume,
that flows past the tumor, becomes loaded with the antitumor drug that diffuses out of the microcapsules, thus
increasing the chemotherapeutic dose to the tumor cells. The use of multiple drugs within the same microcapsule can
provide an opportunity to design microcapsules specifically for chemoembolizafion treatments. Multiple.drug
microcapsules also could be used to deliver first a chemotherapeutic drug wnich would kill tumor cells, and then an
immuno-adjuvant (tumor necrosis factor) or immunological stimulant (e.g. Interferon-y) that would enhance the
patient's immune response to the tumor.
Multiple-drug microcapsules can also be used to deliver combinations of chemotherapeutic drugs to tumors
that are located in privileged sites, such as brain tumors. An example would be the simultaneous delivery of different
types of drugs, e.g. Diaziquone and Cis-platinum, to brain tumors via the carotid artery [ 15]. Multi-layered micro-
capsules could also be used to treat deep infections that are resistant to systemic antibiotics. In these applications, one
or more antibiotics could be sequentially delivered or a immuno-stimulanting cytokine (Interleukin-1) could be
delivered to the site of the infection. Multi-layered microcapsules can be designed to protect active forms of urokinase
and other thrombolytic enzymes until they arc delivered and entrapped at the local site of a blood clot, where therapeutic
doses of the enzyme can diffuse out to dissolve the unwanted embolism. These immiscible-liquid diffusion methods
also could be used for encapsulating certain labile drugs to make microcapsules for special purpose drug delivery
systems, esp. those designed to deliver drugs via the nasal or buccal mucosa or via inhalation directly to the lungs.
Examples include protected delivery of mucolytic DNasc for sustained release treatment of cyctic fibrosis [16] and al-
anti-trypsin for patients with deficiencies in the lung epithelium [17].
Our Earth-based research is now directed towards elimination of certain specific limitations of the liquid-
liquid dispersion method of forming multi-lameilar microcapsules by modification of organic co-surfactants to
improve the efficiency of initial microcapsule formation, characterization of those microparticles, then addition of an
electrostatic coating step to create the final polymer skin in a more traditional fashion. These microcapsules will
then be characterized and compared with those formed in microgravity. Another series of microgravity experiments
is planned for the CMIX-3 payload now targeted to fly on Shuttle STS-67 mission in the fall of 1994. The data will
be used to develop a new microencapsulation system that can be used for future commercial and microgravity
encapsulation research. A joint Patent Disclosure has been prepared by NASA-JSC and the Institute for Research
(IRI) to enable future commercial applications of this new microencapsulation technology.
SUMMARY
A new method of forming muiti-lamellar microcapsules has been developed with the aid of microgravity experi-
ments that eliminate the density-driven portions of phase separations that occur with immiscible liquids having
different densities. Experiments on four different space missions produced unique microcapsules of Cis-platinum
(antitumor drug), amoxicillin (antibio-tic) and urokinase (fibrinolytic enzyme) that were co-encapsulated with
iodinated poppy seed oil, which is a radio-contrast medium. Microcapsules also were formed with crystals of Cis-
platinum or amoxicillin inside the aqueous liquid core. Two different solvent systems were used, based on either
aqueous-soluble phospholipids and polymers or a system using aqueous-soluble drugs dispersed in alcohol solutions
containing polyglycerides which form a tough outer skin around the liquid phases of the microcapsules. The
formation of microcapsules with alternating hydrophilic and hydrophobic layers offers new advantages for drug
delivery systems that are designed specifically for intravascular administration. Microcapsules can now be designed
for chemoembolization and multiple-drug chemotherapy of vascularized tumors. Microcapsules containing the
radioconU'ast medium can be monitored by radiologists during intravascular administration. Other medical
applications include multiple- drug therapy of resistant infections, blood clots and inhalation delivery of labile
proteins to lung tissues.
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Figure 1. Multi-lamellar rnicrocapsules Figure 2. Microcapsules containing IPO.
Figure 3. Cis-platinum crystals in microcapsules. Figure 4. Amoxicillin crystals in microcapsules
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Figure 5. Four units of Materials Dispersion Apparatus (MDA) automated mini-lab
configured for sounding rocket flights. Photo courtesy of ITA, Inc.
Figure 6. MDAs configured for the CMIX payload that flew in the Shuttle Middeck on
STS-52 and STS-56 missions. Photo courtesy of ITA, Inc.
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